Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Exploration of OX40 (CD134) Expression Levels in Sarcoma Specimens and Its Clinical Application in Prognosis Determination

NCT06751251 is registered in ClinicalTrials.gov with Peking University People's Hospital as lead sponsor.

NCT NCT06751251
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06751251 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Exploration of OX40 (CD134) Expression Levels in Sarcoma Specimens and Its Clinical Application in Prognosis Determination
Lead sponsor
Peking University People's Hospital
Phase
Observational
Overall status
Active, not recruiting
Start date
January 1, 2025
Completion date
October 1, 2026
Enrollment
200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

biomarkers, progression, sarcoma